Trump Accelerates Psychedelic Research Following Direct Text from Joe Rogan
In a remarkable development for US drug policy, President Donald Trump has signed a sweeping executive order to fast-track federal research into psychedelic substances. The decision came after a direct text message exchange with influential podcast host Joe Rogan, escalating rapidly into official government action within just days.
From Private Text to Public Policy
The extraordinary chain of events began when Rogan sent President Trump information about ibogaine, a powerful psychedelic substance that some military veterans have reportedly used successfully to treat post-traumatic stress disorder and opioid addiction. The podcast host included data on the treatment's reported success rates in his communication with the president.
'The text message came back: "Sounds great. Do you want FDA approval? Let's do it,"' Rogan recounted during a subsequent White House event. 'It was literally that quick.'
Weeklong Policy Sprint
What followed was described by Centers for Medicare and Medicaid Services Administrator Mehmet Oz as an 'unimaginable task' - a weeklong sprint to transform a private exchange into comprehensive federal policy. By Saturday afternoon, Trump had signed the executive order in the Oval Office, directing his administration to accelerate research and regulatory review for certain psychedelic drugs.
'In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,' Trump declared during the signing ceremony.
Behind-the-Scenes Momentum
While Rogan's involvement appears to have pushed the issue to the top of the administration's agenda, officials had already been working for months on ways to expand access to psychedelic therapies. Health and Human Services Secretary Robert F. Kennedy Jr. had made the issue a priority, with aides including Calley Means and Dr. Heidi Overton helping to advance the effort once Trump signaled his approval.
Regulatory Changes and Expedited Review
The executive order contains several significant provisions that could dramatically alter the regulatory landscape for psychedelic substances. It directs the Food and Drug Administration to expedite review of drugs designated as 'breakthrough therapies,' encourages enhanced data sharing between federal agencies, and opens the door to rapid rescheduling of psychedelics if they receive approval.
FDA Commissioner Dr. Marty Makary announced that the agency will issue national priority vouchers allowing certain drugs to move through the approval process in weeks rather than months. This represents a dramatic shift for substances that remain illegal under federal law and are currently classified alongside drugs such as heroin.
Awkward Oval Office Dynamics
The signing ceremony revealed some tension among the participants, with President Trump barely turning to acknowledge Rogan and Kennedy during the event. Rogan could be seen lingering in the background of the tightly packed Oval Office as the president signed the document.
'We all respect Joe, he's a little bit more liberal,' Trump remarked during the signing. 'It's OK.'
Potential Impact and Future Implications
The president emphasized that the directive would help 'dramatically accelerate' access to potential treatments that could benefit millions of Americans. 'If these turn out to be as good as people are saying, it's going to have a tremendous impact,' Trump stated.
This executive order marks one of the most significant shifts in US drug policy in recent decades, potentially opening new avenues for mental health treatment while raising questions about the influence of private citizens on federal policymaking. The accelerated research could lead to new therapeutic options for conditions that have proven resistant to conventional treatments, particularly among veteran populations.
